Characterization of Influenza A(H1N1)pdm09 Viruses Isolated in the 2018–2019 and 2019–2020 Influenza Seasons in Japan
Abstract
:1. Introduction
2. Materials and Methods
2.1. Ethics Statement
2.2. Cells
2.3. Virus Isolation and Sequencing
2.4. Viruses
2.5. Phylogenetic Analysis
2.6. Structural Analysis
2.7. Plasma Samples
2.8. Hemagglutination Inhibition (HI) Assay
2.9. Virus Neutralization Assay
2.10. Antigenic Cartography
2.11. Statistical Analysis
3. Results
3.1. Genetic Characterization of A(H1N1)pdm09 Viruses Isolated during the 2018–2019 and 2019–2020 Influenza Seasons in Japan
3.2. Antigenic Characterization of A(H1N1)pdm09 Viruses with the D187A and Q189E Substitutions
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bouvier, N.M.; Palese, P. The Biology of Influenza Viruses. Vaccine 2008, 26, D49–D53. [Google Scholar] [CrossRef] [PubMed]
- Virelizier, J.L. Host Defenses against Influenza Virus: The Role of Anti-Hemagglutinin Antibody. J. Immunol. 1975, 115, 434–439. [Google Scholar] [CrossRef] [PubMed]
- Caton, A.J.; Brownlee, G.G.; Yewdell, J.W.; Gerhard, W. The Antigenic Structure of the Influenza Virus A/PR/8/34 Hemagglutinin (H1 Subtype). Cell 1982, 31, 417–427. [Google Scholar] [CrossRef] [PubMed]
- Gerhard, W.; Yewdell, J.; Frankel, M.E.; Webster, R. Antigenic Structure of Influenza Virus Haemagglutinin Defined by Hybridoma Antibodies. Nature 1981, 290, 713–717. [Google Scholar] [CrossRef]
- Matsuzaki, Y.; Sugawara, K.; Nakauchi, M.; Takahashi, Y.; Onodera, T.; Tsunetsugu-Yokota, Y.; Matsumura, T.; Ato, M.; Kobayashi, K.; Shimotai, Y.; et al. Epitope Mapping of the Hemagglutinin Molecule of A/(H1N1)Pdm09 Influenza Virus by Using Monoclonal Antibody Escape Mutants. J. Virol. 2014, 88, 12364–12373. [Google Scholar] [CrossRef]
- Xu, R.; Ekiert, D.C.; Krause, J.C.; Hai, R.; Crowe, J.E.; Wilson, I.A. Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus. Science 2010, 328, 357–360. [Google Scholar] [CrossRef]
- Koel, B.F.; Burke, D.F.; Bestebroer, T.M.; van der Vliet, S.; Zondag, G.C.M.; Vervaet, G.; Skepner, E.; Lewis, N.S.; Spronken, M.I.J.; Russell, C.A.; et al. Substitutions near the Receptor Binding Site Determine Major Antigenic Change during Influenza Virus Evolution. Science 2013, 342, 976–979. [Google Scholar] [CrossRef]
- Xu, Q.; Wang, W.; Cheng, X.; Zengel, J.; Jin, H. Influenza H1N1 A/Solomon Island/3/06 Virus Receptor Binding Specificity Correlates with Virus Pathogenicity, Antigenicity, and Immunogenicity in Ferrets. J. Virol. 2010, 84, 4936–4945. [Google Scholar] [CrossRef]
- Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans. N. Engl. J. Med. 2009, 360, 2605–2615. [CrossRef]
- Linderman, S.L.; Chambers, B.S.; Zost, S.J.; Parkhouse, K.; Li, Y.; Herrmann, C.; Ellebedy, A.H.; Carter, D.M.; Andrews, S.F.; Zheng, N.-Y.; et al. Potential Antigenic Explanation for Atypical H1N1 Infections among Middle-Aged Adults during the 2013-2014 Influenza Season. Proc. Natl. Acad. Sci. USA 2014, 111, 15798–15803. [Google Scholar] [CrossRef] [Green Version]
- Melidou, A.; Hungnes, O.; Pereyaslov, D.; Adlhoch, C.; Segaloff, H.; Robesyn, E.; Penttinen, P.; Olsen, S.J.; Redlberger-Fritz, M.; Popow-Kraupp, T.; et al. Predominance of Influenza Virus A(H3N2) 3C.2a1b and A(H1N1)Pdm09 6B.1A5A Genetic Subclades in the WHO European Region, 2018–2019. Vaccine 2020, 38, 5707–5717. [Google Scholar] [CrossRef]
- Korsun, N.; Daniels, R.; Angelova, S.; Ermetal, B.; Grigorova, I.; Voleva, S.; Trifonova, I.; Kurchatova, A.; McCauley, J. Genetic Diversity of Influenza A Viruses Circulating in Bulgaria during the 2018–2019 Winter Season. J. Med. Microbiol. 2020, 69, 986–998. [Google Scholar] [CrossRef]
- Opanda, S.; Bulimo, W.; Gachara, G.; Ekuttan, C.; Amukoye, E. Assessing Antigenic Drift and Phylogeny of Influenza A (H1N1) Pdm09 Virus in Kenya Using HA1 Sub-Unit of the Hemagglutinin Gene. PLoS ONE 2020, 15, e0228029. [Google Scholar] [CrossRef]
- Rose, A.; Kissling, E.; Emborg, H.-D.; Larrauri, A.; McMenamin, J.; Pozo, F.; Trebbien, R.; Mazagatos, C.; Whitaker, H.; Valenciano, M.; et al. Interim 2019/20 Influenza Vaccine Effectiveness: Six European Studies, September 2019 to January 2020. Eurosurveillance 2020, 25, 2000153. [Google Scholar] [CrossRef]
- Gubareva, L.V.; Mishin, V.P.; Patel, M.C.; Chesnokov, A.; Nguyen, H.T.; Cruz, J.D.L.; Spencer, S.; Campbell, A.P.; Sinner, M.; Reid, H.; et al. Assessing Baloxavir Susceptibility of Influenza Viruses Circulating in the United States during the 2016/17 and 2017/18 Seasons. Eurosurveillance 2019, 24, 1800666. [Google Scholar] [CrossRef]
- Jones, J.C.; Pascua, P.N.Q.; Fabrizio, T.P.; Marathe, B.M.; Seiler, P.; Barman, S.; Webby, R.J.; Webster, R.G.; Govorkova, E.A. Influenza A and B Viruses with Reduced Baloxavir Susceptibility Display Attenuated In Vitro Fitness but Retain Ferret Transmissibility. Proc. Natl. Acad. Sci. USA 2020, 117, 8593–8601. [Google Scholar] [CrossRef]
- McKimm-Breschkin, J.L. Influenza Neuraminidase Inhibitors: Antiviral Action and Mechanisms of Resistance. Influenza Other Respir. Viruses 2013, 7 (Suppl. S1), 25–36. [Google Scholar] [CrossRef]
- Noshi, T.; Kitano, M.; Taniguchi, K.; Yamamoto, A.; Omoto, S.; Baba, K.; Hashimoto, T.; Ishida, K.; Kushima, Y.; Hattori, K.; et al. In Vitro Characterization of Baloxavir Acid, a First-in-Class Cap-Dependent Endonuclease Inhibitor of the Influenza Virus Polymerase PA Subunit. Antivir. Res. 2018, 160, 109–117. [Google Scholar] [CrossRef]
- Pizzorno, A.; Bouhy, X.; Abed, Y.; Boivin, G. Generation and Characterization of Recombinant Pandemic Influenza A(H1N1) Viruses Resistant to Neuraminidase Inhibitors. J. Infect. Dis. 2011, 203, 25–31. [Google Scholar] [CrossRef]
- Takada, K.; Kawakami, C.; Fan, S.; Chiba, S.; Zhong, G.; Gu, C.; Shimizu, K.; Takasaki, S.; Sakai-Tagawa, Y.; Lopes, T.J.S.; et al. A Humanized MDCK Cell Line for the Efficient Isolation and Propagation of Human Influenza Viruses. Nat. Microbiol. 2019, 4, 1268–1273. [Google Scholar] [CrossRef]
- Kärber, G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch. Exp. Pathol. Pharmakol. 1931, 162, 480–483. [Google Scholar] [CrossRef]
- Tamura, K.; Stecher, G.; Kumar, S. MEGA11: Molecular Evolutionary Genetics Analysis Version 11. Mol. Biol. Evol. 2021, 38, 3022–3027. [Google Scholar] [CrossRef] [PubMed]
- Smith, D.J.; Lapedes, A.S.; de Jong, J.C.; Bestebroer, T.M.; Rimmelzwaan, G.F.; Osterhaus, A.D.M.E.; Fouchier, R.A.M. Mapping the Antigenic and Genetic Evolution of Influenza Virus. Science 2004, 305, 371–376. [Google Scholar] [CrossRef] [PubMed]
- Guarnaccia, T.; Carolan, L.A.; Maurer-Stroh, S.; Lee, R.T.C.; Job, E.; Reading, P.C.; Petrie, S.; McCaw, J.M.; McVernon, J.; Hurt, A.C.; et al. Antigenic Drift of the Pandemic 2009 A(H1N1) Influenza Virus in a Ferret Model. PLoS Pathog. 2013, 9, e1003354. [Google Scholar] [CrossRef]
- Koel, B.F.; Mögling, R.; Chutinimitkul, S.; Fraaij, P.L.; Burke, D.F.; Vliet, S.; Wit, E.; Bestebroer, T.M.; Rimmelzwaan, G.F.; Osterhaus, A.D.M.E.; et al. Identification of Amino Acid Substitutions Supporting Antigenic Change of Influenza A(H1N1)Pdm09 Viruses. J. Virol. 2015, 89, 3763–3775. [Google Scholar] [CrossRef]
- Li, C.; Hatta, M.; Burke, D.F.; Ping, J.; Zhang, Y.; Ozawa, M.; Taft, A.S.; Das, S.C.; Hanson, A.P.; Song, J.; et al. Selection of Antigenically Advanced Variants of Seasonal Influenza Viruses. Nat. Microbiol. 2016, 1, 16058. [Google Scholar] [CrossRef]
- Suntronwong, N.; Klinfueng, S.; Korkong, S.; Vichaiwattana, P.; Thongmee, T.; Vongpunsawad, S.; Poovorawan, Y. Characterizing Genetic and Antigenic Divergence from Vaccine Strain of Influenza A and B Viruses Circulating in Thailand, 2017–2020. Sci. Rep. 2021, 11, 735. [Google Scholar] [CrossRef]
- Abe, Y.; Takashita, E.; Sugawara, K.; Matsuzaki, Y.; Muraki, Y.; Hongo, S. Effect of the Addition of Oligosaccharides on the Biological Activities and Antigenicity of Influenza A/H3N2 Virus Hemagglutinin. J. Virol. 2004, 78, 9605–9611. [Google Scholar] [CrossRef]
- Sun, X.; Jayaraman, A.; Maniprasad, P.; Raman, R.; Houser, K.V.; Pappas, C.; Zeng, H.; Sasisekharan, R.; Katz, J.M.; Tumpey, T.M. N-Linked Glycosylation of the Hemagglutinin Protein Influences Virulence and Antigenicity of the 1918 Pandemic and Seasonal H1N1 Influenza A Viruses. J. Virol. 2013, 87, 8756–8766. [Google Scholar] [CrossRef]
- Hadfield, J.; Megill, C.; Bell, S.M.; Huddleston, J.; Potter, B.; Callender, C.; Sagulenko, P.; Bedford, T.; Neher, R.A. Nextstrain: Real-Time Tracking of Pathogen Evolution. Bioinformatics 2018, 34, 4121–4123. [Google Scholar] [CrossRef] [Green Version]
- Meijer, A.; Rebelo-de-Andrade, H.; Correia, V.; Besselaar, T.; Drager-Dayal, R.; Fry, A.; Gregory, V.; Gubareva, L.; Kageyama, T.; Lackenby, A.; et al. Global Update on the Susceptibility of Human Influenza Viruses to Neuraminidase Inhibitors, 2012–2013. Antivir. Res. 2014, 110, 31–41. [Google Scholar] [CrossRef]
- Takashita, E.; Daniels, R.S.; Fujisaki, S.; Gregory, V.; Gubareva, L.V.; Huang, W.; Hurt, A.C.; Lackenby, A.; Nguyen, H.T.; Pereyaslov, D.; et al. Global Update on the Susceptibilities of Human Influenza Viruses to Neuraminidase Inhibitors and the Cap-Dependent Endonuclease Inhibitor Baloxavir, 2017–2018. Antivir. Res. 2020, 175, 104718. [Google Scholar] [CrossRef]
- Gubareva, L.V.; Besselaar, T.G.; Daniels, R.S.; Fry, A.; Gregory, V.; Huang, W.; Hurt, A.C.; Jorquera, P.A.; Lackenby, A.; Leang, S.-K.; et al. Global Update on the Susceptibility of Human Influenza Viruses to Neuraminidase Inhibitors, 2015–2016. Antivir. Res. 2017, 146, 12–20. [Google Scholar] [CrossRef]
- Hurt, A.C.; Besselaar, T.G.; Daniels, R.S.; Ermetal, B.; Fry, A.; Gubareva, L.; Huang, W.; Lackenby, A.; Lee, R.T.C.; Lo, J.; et al. Global Update on the Susceptibility of Human Influenza Viruses to Neuraminidase Inhibitors, 2014–2015. Antivir. Res. 2016, 132, 178–185. [Google Scholar] [CrossRef]
- Lackenby, A.; Besselaar, T.G.; Daniels, R.S.; Fry, A.; Gregory, V.; Gubareva, L.V.; Huang, W.; Hurt, A.C.; Leang, S.-K.; Lee, R.T.C.; et al. Global Update on the Susceptibility of Human Influenza Viruses to Neuraminidase Inhibitors and Status of Novel Antivirals, 2016–2017. Antivir. Res. 2018, 157, 38–46. [Google Scholar] [CrossRef]
- Takashita, E.; Meijer, A.; Lackenby, A.; Gubareva, L.; Rebelo-de-Andrade, H.; Besselaar, T.; Fry, A.; Gregory, V.; Leang, S.-K.; Huang, W.; et al. Global Update on the Susceptibility of Human Influenza Viruses to Neuraminidase Inhibitors, 2013–2014. Antivir. Res. 2015, 117, 27–38. [Google Scholar] [CrossRef]
- Fonville, J.M.; Wilks, S.H.; James, S.L.; Fox, A.; Ventresca, M.; Aban, M.; Xue, L.; Jones, T.C.; Le, N.M.H.; Pham, Q.T.; et al. Antibody Landscapes after Influenza Virus Infection or Vaccination. Science 2014, 346, 996–1000. [Google Scholar] [CrossRef]
- Liu, S.T.H.; Behzadi, M.A.; Sun, W.; Freyn, A.W.; Liu, W.-C.; Broecker, F.; Albrecht, R.A.; Bouvier, N.M.; Simon, V.; Nachbagauer, R.; et al. Antigenic Sites in Influenza H1 Hemagglutinin Display Species-Specific Immunodominance. J. Clin. Investig. 2018, 128, 4992–4996. [Google Scholar] [CrossRef] [Green Version]
Influenza Season | Amino Acid Substitution in HA | Subclade | Total | |||||
---|---|---|---|---|---|---|---|---|
6B.1A | 183P-2 | 183P-4 | 183P-5 | 183P-5A | 183P-7 | |||
2018–2019 | N156K | 0 | 8 (7.6%) | 0 | 0 | 1 (1.0%) | 0 | 9 (8.6%) |
D187A and Q189E | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
N156S, D187A, and Q189E | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Others | 1 (1.0%) | 23 (21.9%) | 4 (3.8%) | 4 (3.8%) | 62 (59.0%) | 2 (1.9%) | 96 (91.4%) | |
Total | 1 (1.0%) | 31 (29.5%) | 4 (3.8%) | 4 (3.8%) | 63 (60.0%) | 2 (1.9%) | 105 | |
2019–2020 | N156K | 0 | 0 | 0 | 0 | 22 (10.1%) | 0 | 22 (10.1%) |
D187A and Q189E | 0 | 0 | 0 | 0 | 195 (89.4%) | 0 | 195 (89.4%) | |
N156S, D187A, and Q189E | 0 | 0 | 0 | 0 | 1 (0.5%) | 0 | 1 (0.5%) | |
Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Total | 0 | 0 | 0 | 0 | 218 (100%) | 0 | 218 |
Vaccine Strain: | Ferret ID Immunized against: | ||||||||
---|---|---|---|---|---|---|---|---|---|
Singapore a | WD039-0 b | GR156 e | GR253 f | ||||||
111 | 112 | 121 | 122 | 131 | 132 | 141 | 142 | ||
2017–2019 season | Singapore a | 2048 | 1024 | 1024 | 2048 | 1024 | 4096 | 64 | 64 |
2018–2019 season | WD039-0 b | 1024 | 1024 | 2048 | 2048 | 1024 | 2048 | 128 | 128 |
BB251 c | 2048 | 1024 | 2048 | 4096 | 1024 | 2048 | 128 | 128 | |
2019–2020 season | BB262 d | 1024 | 1024 | 2048 | 2048 | 2048 | 2048 | 16 | 32 |
GR156 e | 1024 | 1024 | 2048 | 4096 | 1024 | 2048 | 16 | 32 | |
GR253 f | 16 | 16 | 32 | 64 | 16 | 32 | 512 | 1024 | |
AC109 g | 32 | 32 | 64 | 128 | 32 | 64 | 1024 | 4096 |
Vaccine Strain: | Ferret ID Immunized against: | ||||||||
---|---|---|---|---|---|---|---|---|---|
Singapore a | WD039-0 b | GR156 e | GR253 f | ||||||
111 | 112 | 121 | 122 | 131 | 132 | 141 | 142 | ||
2017–2019 season | Singapore a | 64 | 64 | 64 | 64 | 32 | 32 | 4 | <4 |
2018–2019 season | WD039-0 b | 64 | 64 | 128 | 256 | 64 | 128 | 8 | 8 |
BB251 c | 64 | 64 | 128 | 256 | 64 | 128 | 8 | 8 | |
2019–2020 season | BB262 d | 64 | 64 | 64 | 128 | 64 | 128 | 4 | 8 |
GR156 e | 32 | 32 | 32 | 64 | 64 | 64 | <4 | 4 | |
GR253 f | <4 | <4 | 4 | 8 | <4 | <4 | 32 | 64 | |
AC109 g | <4 | <4 | 4 | 8 | <4 | 4 | 32 | 64 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Soga, T.; Duong, C.; Pattinson, D.; Sakai-Tagawa, Y.; Tokita, A.; Izumida, N.; Nishino, T.; Hagiwara, H.; Wada, N.; Miyamoto, Y.; et al. Characterization of Influenza A(H1N1)pdm09 Viruses Isolated in the 2018–2019 and 2019–2020 Influenza Seasons in Japan. Viruses 2023, 15, 535. https://doi.org/10.3390/v15020535
Soga T, Duong C, Pattinson D, Sakai-Tagawa Y, Tokita A, Izumida N, Nishino T, Hagiwara H, Wada N, Miyamoto Y, et al. Characterization of Influenza A(H1N1)pdm09 Viruses Isolated in the 2018–2019 and 2019–2020 Influenza Seasons in Japan. Viruses. 2023; 15(2):535. https://doi.org/10.3390/v15020535
Chicago/Turabian StyleSoga, Takuma, Calvin Duong, David Pattinson, Yuko Sakai-Tagawa, Akifumi Tokita, Naomi Izumida, Tamon Nishino, Haruhisa Hagiwara, Noriyuki Wada, Yumi Miyamoto, and et al. 2023. "Characterization of Influenza A(H1N1)pdm09 Viruses Isolated in the 2018–2019 and 2019–2020 Influenza Seasons in Japan" Viruses 15, no. 2: 535. https://doi.org/10.3390/v15020535
APA StyleSoga, T., Duong, C., Pattinson, D., Sakai-Tagawa, Y., Tokita, A., Izumida, N., Nishino, T., Hagiwara, H., Wada, N., Miyamoto, Y., Kuroki, H., Hayashi, Y., Seki, M., Kasuya, N., Koga, M., Adachi, E., Iwatsuki-Horimoto, K., Yotsuyanagi, H., Yamayoshi, S., & Kawaoka, Y. (2023). Characterization of Influenza A(H1N1)pdm09 Viruses Isolated in the 2018–2019 and 2019–2020 Influenza Seasons in Japan. Viruses, 15(2), 535. https://doi.org/10.3390/v15020535